Serial changes of serum endostatin and angiopoietin-1 levels in preterm infants with severe bronchopulmonary dysplasia and subsequent pulmonary artery hypertension

Neonatology

Volumn 106, Issue 1, 2014, Pages 55-61

  Kim, Do Hyun ^a   Kim, Han Suk ^b  

^a Dongguk University Ilsan Hospital   (South Korea)

^b Seoul National University   (South Korea)

Author keywords

Angiopoietin 1; Bronchopulmonary dysplasia; Endostatin; Pulmonary artery hypertension

Indexed keywords

ANGIOGENIC FACTOR; ANGIOPOIETIN 1; ENDOSTATIN; ANGPT1 PROTEIN, HUMAN; BIOLOGICAL MARKER;

ANGIOGENESIS; ARTICLE; BIRTH WEIGHT; BLOOD LEVEL; CLINICAL ARTICLE; COHORT ANALYSIS; DISEASE SEVERITY; FEMALE; GESTATIONAL AGE; HUMAN; INFANCY; INFANT; LUNG DYSPLASIA; MALE; PREMATURITY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PULMONARY HYPERTENSION; AIRWAY PRESSURE; AMNION FLUID; MAJOR CLINICAL STUDY; OXYGEN CONCENTRATION; OXYGEN CONSUMPTION; PROTEIN BLOOD LEVEL; BLOOD; NEWBORN; NONPARAMETRIC TEST; PATHOPHYSIOLOGY;

ANGIOPOIETIN-1; BIOLOGICAL MARKERS; BRONCHOPULMONARY DYSPLASIA; COHORT STUDIES; ENDOSTATINS; HUMANS; HYPERTENSION, PULMONARY; INFANT, NEWBORN; INFANT, PREMATURE; PROSPECTIVE STUDIES; STATISTICS, NONPARAMETRIC;

EID: 84899777732     PISSN: 16617800     EISSN: 16617819     Source Type: Journal    
DOI: 10.1159/000358374     Document Type: Article

References (25)

1. Northway WH Jr, Rosan RC, Porter DY: Pulmonary disease following respirator therapy of hyaline-membrane disease: bronchopul-monary dysplasia. N Engl J Med 1967; 276: 357-368.
2. Bancalari E, Claure N, Sosenko IR: Broncho-pulmonary dysplasia: changes in pathogene-sis, epidemiology and definition. Semin Neo-natol 2003; 8:63-71. (Pubitemid 36356494)
3. Speer CP: Chorioamnionitis, postnatal factors and proinflammatory response in the pathogenetic sequence of bronchopulmonary dysplasia. Neonatology 2009; 95:353-361.
4. Philip AGS: Bronchopulmonary dysplasia: then and now. Neonatology 2012; 102:1-8.
5. Greenough A: Long-term pulmonary outcome in the preterm infant. Neonatology 2008; 93:324-327. (Pubitemid 351799117)
6. Abman SH: Bronchopulmonary dysplasia: a vascular hypothesis. Am J Respir Crit Care Med 2001; 164:1755-1756.
7. Bhatt AJ, Pryhuber GS, Huyck H, Watkins RH, Metlay LA, Maniscalco WM: Disrupted pulmonary vasculature and decreased vascular endothelial growth factor, Flt-1, and TIE-2 in human infants dying with bronchopulmo-nary dysplasia. Am J Respir Crit Care Med 2001; 164:1971-1980. (Pubitemid 33152338)
8. Lassus P, Turanlahti M, Heikkilä P, Anders-son LC, Nupponen I, Sarnesto A, Andersson S: Pulmonary vascular endothelial growth factor and Flt-1 in fetuses, in acute and chronic lung disease, and in persistent pulmonary hypertension of the newborn. Am J Respir Crit Care Med 2001; 164:1981-1987. (Pubitemid 33152339)
9. Parker TA, Abman SH: The pulmonary circulation in bronchopulmonary dysplasia. Semin Neonatol 2003; 8:51-62. (Pubitemid 36356493)
10. Stenmark KR, Abman SH: Lung vascular development: implications for the pathogenesis of bronchopulmonary dysplasia. Annu Rev Physiol 2005; 67:623-661. (Pubitemid 40404504)
11. Khemani E, McElhinney DB, Rhein L, An-drade O, Lacro RV, Thomas KC, Mullen MP: Pulmonary artery hypertension in formerly premature infants with bronchopulmonary dysplasia: clinical features and outcomes in the surfactant era. Pediatrics 2007; 120:1260-1269. (Pubitemid 350223677)
12. Kim DH, Kim HS, Choi CW, Kim EK, Kim BI, Choi JH: Risk factors for pulmonary artery hypertension in preterm infants with moderate or severe bronchopulmonary dysplasia. Neonataology 2012; 101:40-46.
13. Bhat R, Salas AA, Foster C, Carlo WA, Amba-lavanan N: Prospective analysis of pulmonary hypertension in extremely low birth weight infants. Pediatrics 2012; 129:e682-e689.
14. Thébaud B: Angiogenesis in lung development, injury and repair: implications for chronic lung disease of prematurity. Neona-tology 2007; 91:291-297. (Pubitemid 46934214)
15. Moore TR, Cayle JE: The amniotic fluid index in normal human pregnancy. Am J Obstet Gynecol 1990; 162:1168-1173. (Pubitemid 20174030)
16. Jobe AH, Bancalari E: Bronchopulmonary dysplasia. NICHD-NHLBI-ORD Workshop. Am J Respir Crit Care Med 2001; 163:1723-1729.
17. Ogihara T, Kim HS, Hirano K, Imanishi M, Ogihara H, Tamai H, Okamoto R, Mino M: Oxidation products of uric acid and ascorbic acid in preterm infants with chronic lung disease. Biol Neonate 1998; 73:24-33. (Pubitemid 28014519)
18. O'Reilly MS, Boehm T, Shing Y, Fukai N, Va-sios G, Lane WS, Flynn E, Birkhead JR, Olsen BR, Folkman J: Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997; 88:277-285. (Pubitemid 28015876)
19. Abdollahi A, Hahnfeldt P, Maercker C, Gröne HJ, Debus J, Ansorge W, Folkman J, Hlatky L, Huber PE: Endostatin's antiangio-genic signaling network. Mol Cel 2004; 13: 649-663.
20. Janér J, Andersson S, Haglund C, Lassus P: Pulmonary endostatin perinatally and in lung injury of the newborn infant. Pediatrics 2007; 119:e241-e246. (Pubitemid 46397831)
21. Janér J, Andersson S, Kajantie E, Lassus P: Endostatin concentration in cord plasma predicts the development of bronchopulmonary dysplasia in very low birth weight infants. Pediatrics 2009; 123:1142-1146.
22. Makinde T, Agrawal DK: Intra-and extravas-cular transmembrane signaling of angiopoi-etin-1-Tie2 receptor in health and disease. J Cell Mol Med 2008; 12:810-828. (Pubitemid 351718065)
23. Thomas W, Seidenspinner S, Kramer BW, Kawczynska-Leda N, Chmielnicka-Kopac-zyk M, Marx A, Wirbelauer J, Szymankiewicz M, Speer CP: Airway concentrations of an-giopoietin-1 and endostatin in ventilated extremely premature infants are decreased after funisitis and unbalanced with bronchopul-monary dysplasia/death. Pediatr Res 2009; 65: 468-473.
24. Jakkula M, Le Cras TD, Gebb S, Hirth KP, Tuder RM, Voelkel NF, Abman SH: Inhibition of angiogenesis decreases alveolariza-tion in the developing rat lung. Am J Physiol Lung Cell Mol Physiol 2000; 279:L600-L607.
25. Mourani PM, Mullen M, Abman SH: Pulmonary hypertension in bronchopulmonary dysplasia. Prog Pediatr Cardiol 2009; 27:43-48.